News
10h
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
7don MSN
Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...
Novo Nordisk (NVO), the maker of popular obesity ... This week, the Trump administration imposed 25% tariffs on imports ...
6don MSN
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...
Novo Nordisk retains its title as Europe’s most ... Although Mr. Trump postponed tariffs on goods from Canada and Mexico this week, he proceeded with additional tariffs on Chinese goods and ...
Novo Nordisk A/S is prepared for potential tariffs ... Trump has threatened tariffs on key trading partners Canada, Mexico and China, which has left some manufacturing companies scrambling to ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.
Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...
Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback